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Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in 
humans, accounting for nearly 40% of all non-Hodgkin lymphomas. In spite of recent 
advances in mono- clonal antibody therapy, up to 40% of patients eventually relapse 
and die of their disease after treatment with chemo-immunotherapy regimens. Given 
the inability to cure many patients with DLBCL, and the significant toxicity of current 
therapies, better treatment strategies are needed. Functional genomics studies have 
allowed DLBCLs to be subdivided into biologically and clinically relevant disease sub- 
types, which are called germinal center B-cell (GCB-like) type or activated B-cell (ABC-
like) type, based on their transcriptional similarity to the respective populations of 
primary B cells. The ABC-like DLBCLs are generally more refractory to treatment than 
the GCB-like subtype. In spite of these advances, much remains unknown regarding 
the genetic basis and pathophysiology of this aggressive and highly heterogeneous B-
cell malignancy. In this regard, we have recently identified gain of 3q27.2 as being 
significantly  associated  with  adverse  outcome in DLBCL and linked with the ABC-like 
subtype. This lesion includes the BCL6 oncogene, but, surprisingly, using integrative 
analysis of paired DNA copy number and gene expression microarray data, we  found  
no  significant  overexpression of BCL6 transcript in tumors with 3q27 gain, nor did we 
observe coordinate repression of previously identified BCL6 target genes  in  these  
tumors. Furthermore,  transgenic mice that express Bcl6 specifically in mature B cells 
develop lymphomas in only a subset of mice, and these tumors align most significantly 
with the GCB-like stage of murine B-cell development—a very different phenotype than 
aggressive human ABC-like DLBCL, in which genetic alterations of BCL6 are most 
frequently observed. This observation led us to hypothesize that BCL6 may function as 
a “hit-and-run” oncogene that acts at an early stage of B-cell development to repro- 
gram hematopoietic stem/progenitor cells (HS/PCs) for malignancy. To test this 
hypothesis, we generated strains of mice with restricted expression of this oncogene 
within HS/PCs. Despite lack of Bcl6 protein expression, mature non-malignant B cells 
from these mice show coordinate repression of Bcl6 target genes, suggesting a lasting 
imprint from Bcl6-mediated reprogramming within the stem/progenitor compartment. 
These mice go on to develop aggressive and clonal B-cell lymphomas that accumulate 
at a post-germinal center stage of differentiation, in line with human lymphomas in 
which BCL6 alterations are most frequently observed. These results therefore confirm 
that activity of the Bcl6 oncogene restricted to HS/ PCs can induce malignancies in 
mice that are of a post-germinal center stage of differentiation. Bcl6   mediates   
suppression   of   tar- get genes via recruitment of factors that epigenetically modify 
chromatin. We hypothesized that this may elicit changes in DNA methylation, a mark 
that is capable acting in gene silencing memory, and therefore investigated whether 
this may be a potential mechanism for Bcl6-medited “hit-and-run” oncogenesis. Using 
genome-wide DNA methylation profiling of populations of HS/PCs and mature B-cells 
from wild type and Sca1- Bcl6 mice, we identified broad epigenetic changes associated 
with the expression of Bcl6 in HS/PCs. Importantly, a significant subset of these 
changes were found to be maintained from HS/PCs to mature B cells in Sca1–Bcl6 
mice, resulting in these populations being epigenetically more similar to each other 
than to their comparative population from wild-type mice. Together these results 
suggest that the “hit-and-run” role of Bcl6 activity may be manifested via epigenetic 
alterations. This epigenetic memory would maintain gene expression states through 
cell generations without a change in DNA sequence and in the absence of initiating 
signals. In conclusion, we have provided the first evidence of a “hit-and-run” role for 
Bcl6 in the oncogenesis of lymphoma. The implication of these findings is that, if ABC-
like DLBCL occurs via a reprogramming-like mechanism, oncogenes that initiate tumor 
formation might be dispensable for tumor cell survival and/or tumor progression.  
In this context, mutations that activate oncogenes would have a driving role in the 
reprogramming process, but may act as passenger mutations thereafter, or may have a 
secondary role in evolved tumor cell clones. This may provide an explanation for the 
failure of some modern targeted therapies to clear tumor stem cells, despite being 
effective agents against evolved tumor cells. For instance, BCL6 has emerged as a 
potentially important therapeutic target in recent years given its frequent involvement in 
lymphomagenesis and the fact that specific BCL6 inhibitors can kill lymphoma cells in 
vitro and in vivo. If BCL6 was required to maintain lymphoma-repopulating stem cells, 
then such a BCL6-targeted therapy might indeed prove effective in eradicating residual 
tumor cells when translated to the human setting. On the other hand, the fact that 
BCL6 can also contribute to the malignant phenotype through a hit- and-run 
mechanism dependent on aberrant epigenetic programming of HS/PCs raises the 
possibility that tumor cells could emerge that become BCL6-independent. This 
prediction is supported by the fact that certain BCL6-positive DLBCL cell lines such as 
OCI-Ly8 (which contains a BCL6 translocation) and Karpas 422 are not killed by BCL6 
shRNA or BCL6- targeted therapy. From the therapeutic standpoint, this would indicate 
the need to combine BCL6 inhibitors with drugs that can kill these BCL6-independent 
cells. These concepts are therefore central to the full understanding of disease genesis 
and critical for the development of modern therapies aimed at directly addressing such 
genetic lesions. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure1. Bcl6 hit-and-run oncogenesis in lymphoma. Transient introduction of Bcl6 into Hs/PCs was 
sufficient to induce ABC-DLBCL lymphoma through specific genetic/epigenetic changes in Hs/PCs 
that do not interfere with normal B-cell development. This model initially applies to the mouse and the 
role of BCL6 in human DLBCL progenitors is still unknown and an area of future investigation 
